Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli

PLoS One. 2020 May 14;15(5):e0232987. doi: 10.1371/journal.pone.0232987. eCollection 2020.

Abstract

Escherichia coli and Staphylococcus aureus are important agents of urinary tract infections that can often evolve to severe infections. The rise of antibiotic-resistant strains has driven the search for novel therapies to replace the use or act as adjuvants of antibiotics. In this context, plant-derived compounds have been widely investigated. Cuminaldehyde is suggested as the major antimicrobial compound of the cumin seed essential oil. However, this effect is not fully understood. Herein, we investigated the in silico and in vitro activities of cuminaldehyde, as well as its ability to potentiate ciprofloxacin effects against S. aureus and E. coli. In silico analyses were performed by using different computational tools. The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde. For analysis of the possible toxic effects and the theoretical pharmacokinetic parameters of the compound, the Osiris, SwissADME and PROTOX programmes were used. Estimations of cuminaldehyde gastrointestinal absorption, blood brain barrier permeability and skin permeation by using SwissADME; and drug likeness and score by using Osiris, were also evaluated The in vitro antimicrobial effects of cuminaldehyde were determined by using microdilution, biofilm formation and time-kill assays. In silico analysis indicated that cuminaldehyde may act as an antimicrobial and as a membrane permeability enhancer. It was suggested to be highly absorbable by the gastrointestinal tract and likely to cross the blood brain barrier. Also, irritative and harmful effects were predicted for cuminaldehyde if swallowed at its LD50. Good oral bioavailability and drug score were also found for this compound. Cuminaldehyde presented antimicrobial and anti-biofilm effects against S. aureus and E. coli.. When co-incubated with ciprofloxacin, it enhanced the antibiotic antimicrobial and anti-biofilm actions. We suggest that cuminaldehyde may be useful as an adjuvant therapy to ciprofloxacin in S. aureus and E. coli-induced infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Pharmaceutic / administration & dosage
  • Adjuvants, Pharmaceutic / pharmacokinetics
  • Adjuvants, Pharmaceutic / toxicity
  • Administration, Oral
  • Anti-Bacterial Agents / administration & dosage*
  • Benzaldehydes / administration & dosage*
  • Benzaldehydes / pharmacokinetics
  • Benzaldehydes / toxicity
  • Biofilms / drug effects
  • Biofilms / growth & development
  • Biological Availability
  • Ciprofloxacin / administration & dosage*
  • Computer Simulation
  • Cymenes / administration & dosage*
  • Cymenes / pharmacokinetics
  • Cymenes / toxicity
  • Drug Synergism
  • Escherichia coli / drug effects*
  • Escherichia coli / pathogenicity
  • Escherichia coli / physiology
  • Escherichia coli Infections / drug therapy
  • Humans
  • In Vitro Techniques
  • Microbial Sensitivity Tests
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / pathogenicity
  • Staphylococcus aureus / physiology
  • Urinary Tract Infections / drug therapy

Substances

  • Adjuvants, Pharmaceutic
  • Anti-Bacterial Agents
  • Benzaldehydes
  • Cymenes
  • Ciprofloxacin
  • cuminaldehyde

Grants and funding

This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; grant number 3325/2013; finance code 001), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; grant numbers 309046/2016-5 and 305676/2019-9), Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão (FAPEMA; grant number 03207/18) and INCT-INOVAMED (grant number 465430/2014-7). J.P.P. and N.C.F.S. are students receiving grants from FAPEMA. L.F.G. is an undergraduate student receiving a grant from CNPq. D.M.S. is an undergraduate student receiving a grant from the Santander Universidades programme. A.R.C.Jr. and N.M.T.O. are PhD students receiving grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and CAPES, respectively. B.C.d.S. is a MSc student receiving a studentship from Instituto de Pesquisa Pelé Pequeno Príncipe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.